stay updated

Khondrion to attend UMDF Mitochondrial Medicine Symposium 2021

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces its...

Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases

Study will examine the pharmacokinetics, safety and efficacy of sonlicromanol, one of the most advanced disease-modifying drug candidates in...

Khondrion to present at MITO2i Inaugural Research Symposium on mitochondrial medicine and research

NIJMEGEN, the Netherlands – 6 April 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...

Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...

Khondrion announces publication in Scientific Reports outlining an additional anti-inflammatory mode of action for its lead phase IIb-stage drug candidate sonlicromanol

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...

Khondrion joins Consortium researching metabolomic processes to predict and prevent COVID-19

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...

A coffee with the Scientific Advisory Board: Sir Prof. Dr. Emeritus Doug Turnbull, Chairman

How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...